Event will take place on Wednesday, June 26, 2024 in New York CARMIEL, Israel , June 13, 2024 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx ® plant cell based protein expression system, today announced that it will host an in-person investor... Read More

Company to host conference call and webcast today at 8:30 a.m. EDT CARMIEL, Israel , March 14, 2024 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx ® plant cell-based protein expression system, today reported financial results for the fiscal... Read More

Appointment effective as of September 14, 2023; Zeev Bronfeld to retire from the Board of Directors CARMIEL, Israel , Sept. 12, 2023 /PRNewswire / Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx ® plant cell–based protein expression system, today announced... Read More

CARMIEL, Israel , Sept. 6, 2023 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx ® plant cell–based protein expression system, today announced that Dror Bashan , the Company's President and Chief Executive Officer, will present on Wednesday,... Read More

CARMIEL, Israel , Aug. 1, 2023 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American:PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx ® plant cell–based protein expression system, today announced that Dror Bashan , the Company's President and Chief Executive Officer, will present on Wednesday,... Read More

Event will take place on Tuesday, June 27, 2023 in New York CARMIEL, Israel , June 8, 2023 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx ® plant cell–based protein expression system, today announced it will host an in-person KOL breakfast in... Read More

CARMIEL, Israel , May 23, 2023 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx ® plant cell–based protein expression system, today announced that it is set to join the broad-market Russell 3000 ® Index at the conclusion of the 2023 Russell... Read More

Milestone payment triggered by FDA approval of ELFABRIO ® (pegunigalsidase alfa-iwxj) and payable within 30 days of approval CARMIEL, Israel , May 18, 2023 /PRNewswire/ -- Protalix BioTherapeutics, Inc. ( NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx ® plant cell–based protein expression... Read More

PEGylated enzyme replacement therapy designed to provide long half-life* BOSTON and CARMIEL, Israel , May 10, 2023 /PRNewswire/ -- Chiesi Global Rare Diseases, a business unit of the Chiesi Group established to deliver innovative therapies and solutions for people affected by rare diseases, and Protalix BioTherapeutics, Inc. (NYSE American:PLX), a biopharmaceutical company focused on the development and commercialization of... Read More

PEGylated enzyme replacement therapy designed to provide a long half-life PARMA, Italy , BOSTON and CARMIEL, Israel , May 5, 2023 /PRNewswire/ -- Chiesi Global Rare Diseases, a business unit of the Chiesi Group established to deliver innovative therapies and solutions for people affected by rare diseases, and Protalix BioTherapeutics, Inc. (NYSE American:PLX), a biopharmaceutical company focused on the development and... Read More

Company to host conference call and webcast today at 8:30 a.m. EST CARMIEL, Israel , Feb. 27, 2023 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx ® plant cell-based protein expression system, today reported financial results for the... Read More

European Commission decision anticipated in beginning of May 2023 PARMA, Italy and BOSTON and CARMIEL, Israel , Feb. 24, 2023 /PRNewswire/ -- Chiesi Global Rare Diseases, a business unit of the Chiesi Group established to deliver innovative therapies and solutions for people affected by rare diseases, and Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), a biopharmaceutical company, announced today that the... Read More

CARMIEL, Israel , Feb. 21, 2023 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx ® plant cell-based protein expression system, today announced that it will participating in the 19 th Annual WORLD Symposium ™ 2023, taking place February... Read More

Company to host conference call and webcast at 8:30 a.m. EST . CARMIEL, Israel , Feb. 21, 2023 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx ® plant cell-based protein expression system, today announced that it will release its... Read More

Webcast to be held on Monday, December 5 th at 8:30 a.m. EST CARMIEL, Israel , Dec. 4, 2022 /PRNewswire/ -- P rotalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx ® plant cell-based protein expression system, announced today that the Company will host a... Read More

Hackensack, NJ --News Direct-- Protalix BioTherapeutics, Inc. (NYSE AMERICAN: PLX), an Israeli biopharmaceutical company, and Chiesi Global Rare Diseases , a business unit of the Chiesi Group, have resubmitted a Biologics License Application (BLA) for pegunigalsidase alfa (PRX–102), a drug candidate for the treatment of adult patients with Fabry disease. Fabry disease is a rare enzyme deficiency that afflicts 1 in 40,000 to... Read More